In another study, MUC16 was found to be significantly upregulated in ovarian cancer cells, and delivery of MUC16 via dendritic cell (DC)-based vaccines could stimulate CD8+ cytotoxic T lymphocytes (CTLs) to eliminate tumor cells, highlighting the close association between MUC16 and DC-mediated immune responses (213). This evidence concerns the gene MUC16 and ovarian cancer.